Minaris Advanced Therapies: A New Era in Cell Therapy
Minaris Advanced Therapies has emerged as a pivotal player in the vast field of cell therapy. Unveiled during a notable industry conference, this newly formed organization blends the strengths of experienced contract development and manufacturing organizations (CDMOs) with robust testing capabilities. The result is a collaborative powerhouse dedicated to advancing cell therapy solutions.
A Strong Foundation of Acquisitions
Created through the astute strategic acquisitions by an investment firm, Minaris Regenerative Medicine has partnered with esteemed operations from WuXi Advanced Therapies. By strategically bringing these organizations together, Minaris Advanced Therapies establishes itself as a leading global CDMO focused specifically on cell therapy. The corporate headquarters situates in a central business location, unfurling a bright future in biomanufacturing.
State-of-the-Art Infrastructure Across Continents
The company boasts modern facilities approved for commercial production across several key regions, allowing it to manufacture clinical-stage and commercial products efficiently. Facilities are operational in the United States, Europe, and Asia-Pacific. This multinational presence enables Minaris Advanced Therapies to produce an impressive 7,500 GMP batches serving various clients, bolstering its reputation in the biotech sector.
Innovative Offerings and Expertise
Minaris Advanced Therapies currently undertakes the manufacturing of two commercial cell therapies along with testing services for more than 27 additional products. Their advanced capabilities include innovative platforms and extensive experience in developing cell therapies and viral vectors. With a significant history spanning over 25 years in the field of cell therapy, the company is well-equipped to participate in the next generation of therapy solutions.
Solving Industry Challenges
The chairman of Minaris Advanced Therapies, Iain Baird, highlights the ongoing challenges in the cell therapy industry, particularly the transition from small-scale production to large-scale effective manufacturing practices. The company aims to tackle these hurdles directly, enhancing the potential for successful, global commercialization of new therapies.
Empowered Workforce and Expertise
With a talented team of over 1,400 professionals, Minaris Advanced Therapies possesses profound scientific and regulatory expertise. The dedicated testing unit offers essential analytical method development and GMP-grade biosafety testing services. This unparalleled expertise supports both internal and external programs, fostering innovation and compliance.
Accelerating Commercialization
As stated by Eytan Abraham, Ph.D., chief commercial and technology officer, the goal of Minaris is to optimize patient access to cell therapy innovations. By leveraging existing technologies and expertise, the organization is committed to enhancing commercialization processes, reducing costs, and improving turnaround times. The collective capabilities of the organization are designed for speed, scalability, and scientific rigor.
A Uniquely Structured Organization
Minaris Advanced Therapies boasts remarkable attributes that place it at the forefront of the industry:
- A workforce comprising over 1,400 employees adept in manufacturing, quality assurance, and regulatory compliance.
- Extensive infrastructural capacity across six sites, amassing more than 730,000 square feet of operational space.
- 42 clean rooms tailored for commercial use in key locations.
- A commendable track record of exceeding 7,500 GMP batches with a portfolio of commercial products.
- Successful inspections by top global health regulatory agencies.
- Delivers outstanding biosafety testing, having developed 1,700 assays and managing around 10,000 samples yearly.
- Ownership of 22 pioneering patents in discovery services, ensuring a competitive edge in advanced therapies.
About Minaris Advanced Therapies
Minaris Advanced Therapies operates as a distinguished CDMO and testing organization, concentrating solely on cell and gene therapies. Headquartered in a major metropolitan area, it encompasses over 730,000 square feet of production facilities worldwide. By delivering superior manufacturing and testing services supported by scientific expertise, Minaris Advanced Therapies is dedicated to facilitating the development of effective therapies at an accelerated pace.
Media Contact:
Amy Lamperti
Executive Director, Global Marketing
Phone: +1-201-572-1554
Frequently Asked Questions
What is Minaris Advanced Therapies?
Minaris Advanced Therapies is a global CDMO focused on developing, manufacturing, and testing cell therapies.
Where are the facilities located?
They have facilities in major regions across the United States, Europe, and Asia-Pacific, ensuring broad access to their services.
How many employees work at Minaris?
Minaris employs over 1,400 professionals with extensive expertise in the cell therapy field.
What types of products do they manufacture?
Minaris manufactures commercial cell therapies and provides testing services for a range of over 27 commercial products.
What is their mission?
Minaris aims to facilitate the global commercialization of cell therapies by overcoming developmental and manufacturing challenges in the industry.
